uniQure Announces First Patient Treated in Dose-Confirmation Study in Patients with Hemophilia B
The following is an excerpt from a press release from uniQure. Read the press release in its entirety here. uniQure, a leading gene therapy company advancing transformative therapies for patients with severe unmet medical needs, announced it has treated the first patient in its Phase IIb dose-confirmation study of AMT-061, an investigational AAV5-based gene therapy […]